Sigilon Therapeutics, Inc. Profile Avatar - Palmy Investing

Sigilon Therapeutics, Inc.

Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with m…

Biotechnology
US, Cambridge [HQ]
Strategy & Leadership

Officers & BofD Beta

  • Form 3/4/5
  • Proxy DEF-14A

Total Compensation

- No data, only available if we have DEF 14A compensations in place -
Officers
Name & Position Research Last Appearance
- No data available -
Board of Directors (BofD)
Name & Position Research Last Appearance
- No data available -
End of SGTX's Analysis
CIK: 1821323 CUSIP: 82657L107 ISIN: US82657L1070 LEI: - UEI: -
Secondary Listings
SGTX has no secondary listings inside our databases.